ATE271060T1 - Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen - Google Patents

Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen

Info

Publication number
ATE271060T1
ATE271060T1 AT95902653T AT95902653T ATE271060T1 AT E271060 T1 ATE271060 T1 AT E271060T1 AT 95902653 T AT95902653 T AT 95902653T AT 95902653 T AT95902653 T AT 95902653T AT E271060 T1 ATE271060 T1 AT E271060T1
Authority
AT
Austria
Prior art keywords
methods
prophylaxis
treatment
disclosed
novel
Prior art date
Application number
AT95902653T
Other languages
English (en)
Inventor
Scott Hultgren
Meta Kuehn
Zheng Xu
Derek Ogg
Mark Harris
Matti Lepisto
Charles Hal Jones
Jan Kihlberg
Original Assignee
Univ Washington
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Symbicom Ab filed Critical Univ Washington
Application granted granted Critical
Publication of ATE271060T1 publication Critical patent/ATE271060T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95902653T 1993-11-18 1994-11-18 Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen ATE271060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15403593A 1993-11-18 1993-11-18
PCT/US1994/013455 WO1995014028A2 (en) 1993-11-18 1994-11-18 Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections

Publications (1)

Publication Number Publication Date
ATE271060T1 true ATE271060T1 (de) 2004-07-15

Family

ID=22549739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902653T ATE271060T1 (de) 1993-11-18 1994-11-18 Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen

Country Status (10)

Country Link
US (2) US6001823A (de)
EP (1) EP0730601B1 (de)
JP (1) JPH09505309A (de)
AT (1) ATE271060T1 (de)
AU (1) AU704114B2 (de)
CA (1) CA2176808A1 (de)
DE (1) DE69433901T2 (de)
DK (1) DK0730601T3 (de)
ES (1) ES2225834T3 (de)
WO (1) WO1995014028A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3816570B2 (ja) * 1996-02-16 2006-08-30 塩水港精糖株式会社 アシル化剤
US5998381A (en) * 1996-12-06 1999-12-07 Ophidian Pharmaceuticals, Inc. Compounds that bind bacterial pili
US7015309B1 (en) 1999-06-23 2006-03-21 The Wistar Institute Of Anatomy And Biology Pyrrhocoricin-derived peptides, and methods of use thereof
EP1194548A4 (de) * 1999-06-23 2003-06-18 Wistar Inst Von pyrrhocoricin abstammende peptide und verfahren zu deren anwendung
US7041465B1 (en) 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU7470300A (en) * 1999-08-11 2001-03-05 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
AU1760001A (en) * 1999-11-10 2001-06-06 Quest Diagnostics Investments Incorporated Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics and clinical applications
CA2398808A1 (en) * 2000-01-21 2001-07-26 The Wistar Institute Of Anatomy & Biology Biocidal molecules, macromolecular targets and methods of production and use
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
JP2004517653A (ja) * 2000-10-24 2004-06-17 ボシュ・アンド・ロム・インコーポレイテッド カチオン性多糖による、生体材料への細菌付着の予防
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
US7094571B2 (en) * 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US6702983B2 (en) 2001-05-15 2004-03-09 Bausch & Lomb Incorporated Low ionic strength method and composition for reducing bacterial attachment to biomaterials
US7611866B2 (en) * 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
US6916474B2 (en) * 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
CN1684722A (zh) 2002-09-30 2005-10-19 博士伦公司 减少细菌在生物材料和生物医学装置上的粘附
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
ATE441417T1 (de) 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
US7544773B2 (en) 2003-07-14 2009-06-09 Timo Kalevi Korpela Antimicrobials against pathogenic bacteria and method for screening them
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
CA2560074A1 (en) * 2004-03-18 2005-11-03 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
WO2005089733A2 (en) * 2004-03-23 2005-09-29 Vib Vzw Anti-adhesive compounds to prevent and treat bacterial infections
US20070087113A1 (en) * 2005-10-19 2007-04-19 Bausch & Lomb Incorporated Surface-modified medical devices and method of making
US20090142387A1 (en) * 2007-12-03 2009-06-04 Blackwell Richard I Method For Inhibiting Attachment Of Microorganisms To Biomedical Devices
EP2672820B1 (de) 2011-02-07 2019-04-17 The Washington University Mannosidverbindungen und anwendungsverfahren dafür
PL2970353T3 (pl) * 2013-03-12 2018-10-31 Vertex Pharmaceuticals Incorporated Pochodne mannozy do leczenia infekcji bakteryjnych
CN111423479A (zh) 2013-05-30 2020-07-17 华盛顿大学 用于治疗细菌性感染的化合物和方法
EP2878335B1 (de) 2013-11-10 2018-01-03 Brainsgate Ltd. Implantat und implantationssystem für nervenstimulator
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
WO2016126721A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
JP2019509315A (ja) 2016-03-23 2019-04-04 フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疾患の処置に有用なＦｉｍＨのマンノース由来アンタゴニスト
EP3472131B1 (de) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- und 6-hydroxamsäureindane als hdac-inhibitoren
SMT202200435T1 (it) 2018-07-10 2023-01-13 Glaxosmithkline Ip Dev Ltd Composti di c-mannoside utili per il trattamento di infezioni del tratto urinario
BR112021022281A2 (pt) 2019-05-07 2021-12-28 Fimbrion Therapeutics Inc Novos compostos
WO2020254369A1 (en) 2019-06-19 2020-12-24 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh
CN119013006A (zh) * 2022-04-14 2024-11-22 周美吟 艾杜糖醛酸酶及其用途
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE470430B (sv) * 1989-09-18 1994-02-21 Tore Brinck Sätt att utnyttja kvantkemiska metoder vid molekyl-design
US5304660A (en) * 1990-01-08 1994-04-19 Rhone-Poulenc Rorer S.A. Pyran derivatives
EP0464276A1 (de) * 1990-07-02 1992-01-08 International Business Machines Corporation Rechnermodellierungssystem
WO1993002209A1 (en) * 1991-07-22 1993-02-04 The Regents Of The University Of California Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
DK96093D0 (da) * 1993-08-25 1993-08-25 Symbicom Ab Improvements in molecular modelling and drug design

Also Published As

Publication number Publication date
EP0730601B1 (de) 2004-07-14
CA2176808A1 (en) 1995-05-26
WO1995014028A2 (en) 1995-05-26
AU1184495A (en) 1995-06-06
ES2225834T3 (es) 2005-03-16
JPH09505309A (ja) 1997-05-27
DE69433901T2 (de) 2005-07-28
US6153396A (en) 2000-11-28
AU704114B2 (en) 1999-04-15
DE69433901D1 (de) 2004-08-19
WO1995014028A3 (en) 1995-06-15
US6001823A (en) 1999-12-14
DK0730601T3 (da) 2005-06-06
EP0730601A1 (de) 1996-09-11

Similar Documents

Publication Publication Date Title
DE69433901D1 (de) Verbindungen und pharmazeutische zusammensetzungen zur behandlung und prophylaxe bakterieller infektionen
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
HUP9802857A2 (hu) Farnezil-transzferáz gátló hatású 4-merkapto-pirrolidin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
BR0012970A (pt) Compostos e composições antipicornavirais, seus usos farmacêuticos e materiais para a sua sìntese
ATE455786T1 (de) 6-11 bicyclische ketolidderivate
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
BR0016742A (pt) Compostos e composições antipicorna virais, suas aplicações farmacêuticas, e materiais para sua sìntese
BR0002577A (pt) Suspensões orais de trovafloxacina
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
SE9904581D0 (sv) A novel helicobacter pylori-binding substance and use thereof
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE188873T1 (de) Tris-platin-komplexe
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
DE69613975D1 (de) Dialkyltiacumicine
ATE414082T1 (de) Antibiotische tetrahydro-b-carbolinderivative
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
AU2003210850A1 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
BR0309412A (pt) Indol-2-onas como inibidores seletivos da ciclooxigenase-2
DE602004017586D1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
DE602004017214D1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0730601

Country of ref document: EP

EEIH Change in the person of patent owner